1. Market Research
  2. > Biotechnology
  3. > Biological Therapy Market Trends
  4. > Engineered TCR and CAR Immunotherapeutics 2015

Engineered TCR and CAR Immunotherapeutics 2015

  • March 2015
  • -
  • La Merie Publishing
  • -
  • 201 pages

Engineered TCR and CAR Immunotherapeutics 2015:
A comparative analysis of the landscape of and business opportunities with  TCR and CAR antibodies, T cells, NK cells, TILs, DLIs & CTLs

The engineered T cell receptor (TCR) for targeting of intracellur targets not druggable by conventional antibody technologies, and specifically targeted engineered T cells are two of the most promising emerging technologies in immuno-oncology apart from immune checkpoint modulators. The relevance of TCR targeting and engineered T cells is reflected by impressive clinical results with CD19 chimeric antigen receptor (CAR) T cells and outstanding partnering and financing deals concluded within the last two years.

Leveraging the power of T cells by cellular and recombinant immunotherapeutics

- Intra-cellular Targets
- Cell surface targets
- Cellular
- TCR T Cells
- CAR T Cells

- (autologous/allogeneic)
- Recombinant
- Bispecific TCR-anti-CD3
- (e.g. ImmTACs)
- Bispecific antibodies (incl. anti-CD3)


This report "Engineered TCR and CAR Immunotherapeutics 2015: A comparative analysis of the landscape of and business opportunities with  TCR and CAR antibodies, T cells, NK cells, TILs, DLIs & DLIs" as of March 2015 brings you up-to-date regarding key players, key technologies, TCR and CAR immunotherapeutic projects, business deals and private and public financing rounds. The report analyzes the TCR and CAR immunotherapeutic pipelines and stakeholders in the field, especially among Big Pharma/Biotech and technology companies. The report highlights the value of TCR and CAR immunotherapeutics in terms of partnering economic conditions, private financing rounds and (initial) public offerings with the resulting market capitalization of companies.

However, progress in clinical trials and supply of clinical grade batches reveals some major limitations which need to be surmounted and the problems solved if TCR and CAR immunotherapeutics want to become commercially viable and successful products. This report describes the challenges and limitations and identifies solutions provided by new technologies which offer tremendous business opportunities.

Download Sample Pages: Engineered TCR and CAR Immunotherapeutics 2015

This report has been built in a bottom-up basis by desktop search to identify and describe company, product, technology and business/financing profiles which then are evaluated and analyzed with a final outlook describing perspectives with challenges and opportunities.

What will you find in the report?

- Profiles of TCR and CAR immunotherapeutics in development;
- Competitor analysis of CD19 CAR T cells;
- Options to improve CAR T cells regarding efficacy, safety, manufacturing and commercial value;
- Target analysis of TCR T cells in R&D;
- CAR T Cell pipeline in hematology;
- CAR T Cell pipeline in solid tumors;
- Allogeneic TCR and CAR T cells in R&D;
- Universal antibody-targeted CAR T cells and NK cells;
- Pipeline of most promising TILs, NK cells, DLIs and CTLs;
- Technologies needed for next generations of TCR and CAR immunotherapeutics;
- Profiles of biotechnology companies incl. financing and licensing/partnering;
- Profiles and scope of interest of Big Pharma/Biotech companies for TCRs & CARs;
- Stakeholder analysis (established, emerging, non-US, technology providing companies);
- Potential of alternative adoptive immunotherapies with NK cells, TILs, CTLs and DLIs;
- Analysis of major partnering deals between Big pharma and technology companies;
- Economic terms of pharma-biotech deals;
- Opportunities for biotech-biotech deals in the TCR and CAR field;
- Potential to raise private money with TCR and CAR technologies;
- Success in initial public offerings and follow on offerings with TCRs and CARs;
- Limitations and hurdles with current TCR and CAR immunotherapeutics;
- Opportunities for novel TCR and CAR immunotherapeutics;
- Pricing of TCR and CAR immunotherapeutics;
- Aspects of manufacturing and commercialization.


Who will benefit from the report?

- Venture capital, private equity and investment managers;
- Financial analysts;
- CFO;
- Business development and licensing (BDL) specialists;
- Marketing managers;
- CEO, COO and managing directors;
- Corporate strategy, product and portfolio analysts and managers;
- Chief Technology Officer;
- Cell technology and manufacturing specialists;
- Clinical and preclinical development specialists.

Table Of Contents

Engineered TCR and CAR Immunotherapeutics 2015
Engineered TCR and CAR Immunotherapeutics 2015:
A comparative analysis of the landscape of and business opportunities with  TCR and CAR antibodies, T cells, NK cells, TILs, DLIs and CTLs

TABLE OF CONTENTS
1          Introduction  
2          Executive Summary
3          Profiles of TCR and CAR Immunotherapeutics, NK Cells, TILs, DLIs and CTLs 
3.1       TCR Fusion Proteins and Antibodies  

- ALT-801        
- IMCgp100  
- ESK1 / ESKM3.2     

3.2       Autologous TCR T Cells for Solid Tumors and Hematologic Malignancies 

- NY-ESOc259T 
- JCAR016
- TBI-1201      
- TBI-1301  
- BPX-701       

3.3       CD19 CAR T Cells   

- CTL019       
- HuCART19 (HuCTL019)
- JCAR015    
- JCAR017       
- JCAR014       
- KTE-C19     
- CD19-CAR T cells (Takara) 
- BPX-401       

3.4       Other Autologous CAR T Cells for Hematological Malignancies  

- CART123      
- CM-CS1  

3.5       Autologous CAR T Cells for Solid Tumors 

- G2-CAR.OX4028.z.ICD19 

- BPX-601       
- CAR-NKp30/B7H6  
- CART-EGFRvIII     
- CART-meso T cells   

3.6       Allogeneic CAR T Cells       

- UCART19     
- UCART38    
- UCART123   
- UCARTCS1  

3.7       Universal CAR T cells          

- ATTCK20     

3.8       NK Cells, TILs, DLIs and CTLs         

- Natural Killer (NK) cells: Neukoplast / NK-92       
- NK cells: CD16-Neukoplast 
- NK cells: NK-92.ErbB2/Her2       
- Tumor Infiltrating Lymphocytes (TILs): LN-144 (Contego)      
- Donor Lymphocyte Infusion (DLI): BPX-501      
- Cytotoxic T-Lymphocytes (CTLs): EBV-CTL   

4          Pipeline Analysis       

4.1       TCR Antibodies, Fusion Proteins and TCR-like Antibodies      
4.2       TCR T-Cells  
4.3       CD19 CAR T Cells  
4.4       Other CAR T Cells for Hematological Malignancies         
4.5       Other CAR T Cells for Solid Tumors      
4.6       Allogeneic TCR and CAR T Cells    
4.7       Universal, antibody-targeted CAR T Cells
4.8       Natural Killer cells (NK cells), Tumor Infiltrating Lymphocytes (TILs), Donor Lymphocyte Infusions (DLIs) and Cytotoxic T Lymphocytes (CTLs)    

5          Technology Companies       

5.1       Adaptimmune
5.2       Altor Bioscience      
5.3       Applied Immune Technologies (AIT)        
5.4       Atara Biotherapeutics
5.5       Autolus          
5.6       Bellicum Pharmaceuticals     
5.7       Bluebird bio
5.8       Cardio3 BioSciences 
5.9       Cellectis       
5.10     Cellular Biomedicine Group (CBMG)        
5.11     Conkwest      
5.12     CRISPR Therapeutics         
5.13     CytomX    
5.14     Editas Medicine      
5.15     Eureka Therapeutics  
5.16     Immunocore  
5.17     Intellia Therapeutics  
5.18     Intrexon, ZIOPHARM Oncology and MD Anderson        
5.19     Juno Therapeutics     
5.20     Kite Pharma   
5.21     Lion Biotechnologies
5.22     MD Anderson Cancer Center        
5.23     Medigene     
5.24     Nextera          
5.25     Sorrento Therapeutics      
5.26     Takara Bio     
5.27     Transposagen Biopharmaceuticals    
5.28     Unum Therapeutics   

6          Pharmaceutical Companies   

6.1       Amgen           
6.2       AstraZeneca  
6.3       Celgene      
6.4       Eli Lilly          
6.5       GlaxoSmithKline     
6.6       Janssen Biotech     
6.7       Novartis       
6.8       Pfizer 
6.9       Roche 
6.10     Servier

7          Stakeholder Analysis

7.1       TCR Focused Companies     
7.2       Established CAR (and TCR) T Cell Companies       
7.3       Emerging and/or non-US based CAR (and TCR) T Cell Companies
7.4       Technology Providers
7.5.      Pharma Companies in the Field       
7.6       Companies with Alternative Adoptive Cell Therapies: NK Cells, TILs, DLIs and CTLs  

8          Selected Technology Profiles

8.1       Genome Editing Technologies         

- Allogeneic multichain chimeric Antigen Receptor (mcCAR) T-cells         
- CAR T cells and multiplex gene editing (bluebird bio)       
- Genome Editing Technology (Transposagen)

8.2       Switch Technologies 

- Inducible Caspase 9 and inducible MyD88/CD40 Switch Systems         
- RheoSwitch Therapeutic System (RTS) technology

8.3       Non-Viral Gene Transfer      

- Sleeping Beauty 

8.4       Next Generation CAR T Cell Technologies 

- Juno Therapeuticsandlsquo; CAR Technologies 

8.5       Engineered TCR T Cells       
- TCR Engineered T Cell Technology (Adaptimmune)   

8.6       Special Cases of CAR T Cell Construcs     
- Oncyte CAR T Cell Constructs      
- Universal Antibody-Coupled T-cell Receptor (ACTR) technology

9          Business Perspective on TCR and CAR Immunotherapeutics        

9.1       Deals  
9.2       Private Financing Rounds     
9.3       Public Offerings and Market Capitalization of Companies with TCR or CAR Immunotherapeutics    

10        Outlook for TCR and CAR Immunotherapeutics   

10.1     Limitations and Hurdles with current CAR T Cell Therapies         
10.2     Opportunities for Novel TCR and CAR Immunotherapeutics       
10.3     Pricing of CAR and TCR T Cell Products   

10.4     Manufacturing and Commercialization    

11        References     

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Chimeric Antigen Receptor (CAR) T cell Immunotherapy- Competitive Landscape, Technology and Pipeline Analysis, 2016

Chimeric Antigen Receptor (CAR) T cell Immunotherapy- Competitive Landscape, Technology and Pipeline Analysis, 2016

  • $ 2450
  • Industry report
  • November 2016
  • by Delve Insight

DelveInsight Report, “Chimeric Antigen Receptor (CAR) T cell Immunotherapy- Competitive Landscape, Technology and Pipeline Analysis, 2016” emphasizes on the currently active CAR-T cell products in ...

Flat-Rate Access to R&D Database & Reports from La Merie Publishing

Flat-Rate Access to R&D Database & Reports from La Merie Publishing

  • $ 8470
  • Industry report
  • November 2016
  • by La Merie Publishing

Flat-Rate Access to R&D Database & Reports from La Merie Publishing - R&D Drug Pipeline Database: 1-Year Subscription - Flat-Rate Subscription to La Merie Publishing Reports & News Services A one-yea ...

Bioprinting: Technologies and Global Markets

Bioprinting: Technologies and Global Markets

  • $ 6650
  • Industry report
  • October 2016
  • by BCC Research

Use this report to: - Understand market dynamics of bioprinting technologies, applications, and end-user industries. - Assess specific bioprinting-related industries, including 3-D cell culture; bioinks; ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.